MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

(Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

Explore the causes of itching in liver diseases and tips to relieve discomfort. Learn about treatments for pruritus and when ...

Itchy skin, or pruritus, can result from conditions like eczema or dermatitis. Less commonly, it can stem from conditions such as kidney failure and liver disease. Some causes of itching affect ...

Specific dermatoses of pregnancy, according to the reclassification by Ambros-Rudolph et al. 8. Ambros-Rudolph et al. described two clinical presentations: the eczematous type (E-type) with a classic ...

Sometimes, it may be a symptom of an underlying condition. Itchy skin at night, called nocturnal pruritus, can be severe enough to disrupt sleep regularly. Why this happens can range from natural ...

Cholestasis is a condition in which the flow of bile from the gall bladder to the duodenum is impaired. The condition can result from obstruction of the extrahepatic or intrahepatic bile ducts ...

UDCA has been shown to improve biochemical parameters and alleviate symptoms like jaundice and pruritus in DILI patients, particularly in those with cholestatic patterns. Moreover, there is ...

Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic ...

We initiated the Phase 3 EXPAND study of LIVMARLI in broader settings of cholestatic pruritus, a significant growth opportunity for the brand. And beyond LIVMARLI, we achieved positive interim ...

LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026. Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS ...